SeleRNA
Pioneering cardiomyocyte-selective modRNA translation to transform cardiac care
Our platform harnesses cardiomyocyte-selective modRNA translation (CM SMRTs) to deliver therapeutic proteins directly to heart muscle cells. This groundbreaking approach transforms cardiomyocytes into on-site biomanufacturers of therapeutic proteins, eliminating the need for invasive gene-therapy surgery and dramatically minimizing off-target effects.
Our team is actively refining the CM SMRTs platform by optimizing delivery methods, lipid-nanoparticle composition, and dosing regimens to achieve precise, high-efficacy translation of our therapeutic targets in large-animal models.
Regenerating heart tissue after myocardial infarction to restore cardiac function and prevent heart failure formation.
Protecting the heart from chemotherapy-induced cardiotoxicity, enabling cancer patients to receive life-saving treatments safely.
Delivering therapeutic proteins with unprecedented selectivity, minimizing systemic side effects while maximizing cardiac benefit.
Why CM SMRTs represents a paradigm shift in cardiac therapeutics
Unlike traditional gene therapy requiring open-heart surgery, our modRNA approach enables minimally invasive delivery through systemic administration.
Modified mRNA provides temporary, controlled protein expression without permanently altering the genome—a safer, more controllable approach.
Our platform achieves unprecedented selectivity for cardiomyocytes, dramatically reducing off-target effects in other organs.
Demonstrated efficacy in large-animal models provides strong translational potential for first-in-human trials.
Our preclinical successes have moved us rapidly toward first-in-human trials. We have demonstrated:
These milestones bring us closer to delivering life-changing treatments to patients suffering from heart disease and chemotherapy-related cardiac damage.